ROSES-S：世界卫生组织关于严重急性呼吸综合征冠状病毒 2 型血清流行病学研究报告的声明。
ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2.
出版信息
Influenza Other Respir Viruses. 2021 Sep;15(5):561-568. doi: 10.1111/irv.12870. Epub 2021 Jun 26.
Abstract
Well-designed population-based seroepidemiologic studies can be used to refine estimates of infection severity and transmission, and are therefore an important component of epidemic surveillance. However, the interpretation of the results of seroepidemiologic studies for SARS-CoV-2 has been hampered to date principally by heterogeneity in the quality of the reporting of the results of the study and a lack of standardized methods and reporting. We provide here the ROSES-S: Reporting of Seroepidemiologic studies-SARS-CoV-2. This is an updated checklist of 22 items that should be included in the reporting of all SARS-CoV-2 seroepidemiologic studies, irrespective of study design.
摘要
精心设计的基于人群的血清流行病学研究可用于改进对感染严重程度和传播的估计，因此是流行监测的重要组成部分。然而，迄今为止，SARS-CoV-2 血清流行病学研究结果的解释主要受到研究结果报告质量的异质性以及缺乏标准化方法和报告的阻碍。我们在此提供 ROSES-S：SARS-CoV-2 血清流行病学研究报告。这是一份更新的清单，其中包含 22 项条目，应包含在所有 SARS-CoV-2 血清流行病学研究的报告中，无论研究设计如何。
相似文献
1
ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2.
Influenza Other Respir Viruses. 2021 Sep;15(5):561-568. doi: 10.1111/irv.12870. Epub 2021 Jun 26.
2
Adherence of SARS-CoV-2 Seroepidemiologic Studies to the ROSES-S Reporting Guideline During the COVID-19 Pandemic.
Influenza Other Respir Viruses. 2024 Jul;18(7):e13283. doi: 10.1111/irv.13283.
3
CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement.
Influenza Other Respir Viruses. 2017 Jan;11(1):2-14. doi: 10.1111/irv.12411. Epub 2016 Aug 9.
4
Prevalence of SARS-CoV-2 antibodies among nurses: A systematic review and meta-analysis.
J Clin Nurs. 2022 Jun;31(11-12):1557-1569. doi: 10.1111/jocn.16009. Epub 2021 Sep 27.
5
Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
Public Health. 2021 Jan;190:132-134. doi: 10.1016/j.puhe.2020.11.014. Epub 2020 Nov 24.
6
COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past trends and future patterns.
Lancet Glob Health. 2022 Aug;10(8):e1099-e1114. doi: 10.1016/S2214-109X(22)00233-9. Epub 2022 Jun 1.
7
SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil.
Emerg Infect Dis. 2022 Apr;28(4):734-742. doi: 10.3201/eid2804.211961. Epub 2022 Feb 18.
8
Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.
Emerg Infect Dis. 2022 Jun;28(6):1233-1236. doi: 10.3201/eid2806.212580. Epub 2022 Apr 26.
9
SARS-CoV-2 incidence, seroprevalence, and COVID-19 vaccination coverage in the homeless population: a systematic review and meta-analysis.
Front Public Health. 2023 Oct 10;11:1044788. doi: 10.3389/fpubh.2023.1044788. eCollection 2023.
10
Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study.
CMAJ Open. 2023 Apr 4;11(2):E305-E313. doi: 10.9778/cmajo.20220045. Print 2023 Mar-Apr.
引用本文的文献
1
Adherence of SARS-CoV-2 Seroepidemiologic Studies to the ROSES-S Reporting Guideline During the COVID-19 Pandemic.
Influenza Other Respir Viruses. 2024 Jul;18(7):e13283. doi: 10.1111/irv.13283.
2
Risk factors for recognized and unrecognized SARS-CoV-2 infection: a seroepidemiologic analysis of the Prospective Urban Rural Epidemiology (PURE) study.
Microbiol Spectr. 2024 Feb 6;12(2):e0149223. doi: 10.1128/spectrum.01492-23. Epub 2024 Jan 12.
3
Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response.
Trop Med Infect Dis. 2023 Nov 4;8(11):493. doi: 10.3390/tropicalmed8110493.
4
The increasing complexity of arbovirus serology: An in-depth systematic review on cross-reactivity.
PLoS Negl Trop Dis. 2023 Sep 22;17(9):e0011651. doi: 10.1371/journal.pntd.0011651. eCollection 2023 Sep.
5
Household transmission investigation: Design, reporting and critical appraisal.
Influenza Other Respir Viruses. 2023 Jun 15;17(6):e13165. doi: 10.1111/irv.13165. eCollection 2023 Jun.
6
A framework for seroepidemiologic investigations in future pandemics: insights from an evaluation of WHO's Unity Studies initiative.
Health Res Policy Syst. 2023 May 16;21(1):34. doi: 10.1186/s12961-023-00973-z.
7
SARS-CoV-2 seroprevalence and determinants for salivary seropositivity among pupils and school staff: a prospective cohort study.
Epidemiol Infect. 2023 Apr 24;151:e75. doi: 10.1017/S0950268823000584.
8
Transmission of SARS-CoV-2 in standardised first few X cases and household transmission investigations: A systematic review and meta-analysis.
Influenza Other Respir Viruses. 2022 Sep;16(5):803-819. doi: 10.1111/irv.13002. Epub 2022 Jun 16.
9
Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance.
Epidemics. 2022 Dec;41:100645. doi: 10.1016/j.epidem.2022.100645. Epub 2022 Oct 20.
10
U.S. CDC support to international seroprevalence surveys, May 2020-February 2022.
PLOS Glob Public Health. 2022 Aug 5;2(8). doi: 10.1371/journal.pgph.0000658.
本文引用的文献
1
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.
PLoS One. 2021 Jun 23;16(6):e0252617. doi: 10.1371/journal.pone.0252617. eCollection 2021.
2
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis.
Lancet Glob Health. 2021 May;9(5):e598-e609. doi: 10.1016/S2214-109X(21)00026-7. Epub 2021 Mar 8.
3
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.
Clin Microbiol Infect. 2021 Mar;27(3):331-340. doi: 10.1016/j.cmi.2020.10.020. Epub 2020 Oct 24.
4
Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.
Signal Transduct Target Ther. 2020 Sep 2;5(1):180. doi: 10.1038/s41392-020-00301-9.
5
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis.
BMJ. 2020 Jul 1;370:m2516. doi: 10.1136/bmj.m2516.
6
Antibody tests for identification of current and past infection with SARS-CoV-2.
Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652.
7
Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis.
Diagnostics (Basel). 2020 May 19;10(5):319. doi: 10.3390/diagnostics10050319.
8
Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control.
Front Immunol. 2020 Apr 24;11:879. doi: 10.3389/fimmu.2020.00879. eCollection 2020.
9
Weighing serological evidence of human exposure to animal influenza viruses - a literature review.
Euro Surveill. 2016 Nov 3;21(44). doi: 10.2807/1560-7917.ES.2016.21.44.30388.
10
CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement.
Influenza Other Respir Viruses. 2017 Jan;11(1):2-14. doi: 10.1111/irv.12411. Epub 2016 Aug 9.
Zotero 插件